Titlebook: Diabetic Neuropathy; Clinical Management Aristidis Veves,Rayaz A. Malik Book 20072nd edition Humana Press 2007 Diabetes.Diabetes mellitus.N

palliative

书目名称Diabetic Neuropathy影响因子(影响力)




书目名称Diabetic Neuropathy影响因子(影响力)学科排名




书目名称Diabetic Neuropathy网络公开度




书目名称Diabetic Neuropathy网络公开度学科排名




书目名称Diabetic Neuropathy被引频次




书目名称Diabetic Neuropathy被引频次学科排名




书目名称Diabetic Neuropathy年度引用




书目名称Diabetic Neuropathy年度引用学科排名




书目名称Diabetic Neuropathy读者反馈




书目名称Diabetic Neuropathy读者反馈学科排名

Calculus

-to-date bibliographies at the end of each chapterIn this newly updated, second edition, leading medical specialists critically review for the general practitioner the latest techniques for the clinical management of diabetic neuropathy. These authoritative contributors focus on the practical aspect

分离

liposuction

Malte Jansen,Aleksander Kocaj,Petra Stanat the damaging effect of the polyol pathway. The effect of treatment is also described with sonic hedgehog in preventing reduced nerve conduction velocity and normalising expression of genes coding for endoskeletal proteins, which may be instrumental in preserving the integrity of the distal axon.

财主

防水

Alexandra Kreuzpointner,Ralf Reißerdefined end points and the inability to produce an inhibitor that achieves satisfactory tissue penetration and enzyme inhibition are other major contributing factors for this failure. This chapter focuses on the clinical trials that have examined the effect of all tested ARIs on human diabetic neuropathy.

防水

tolerance

哑巴

Punch Skin Biopsy in Diabetic Neuropathy,r impaired glucose tolerance and can be the only objective measure of neuropathy in these patients. The accessibility of cutaneous nerve fibers has also given rise to several nerve injury paradigms from which regeneration can be efficiently measured. The chapter will review the skin biopsy technique and recent findings with respect to diabetes.

信徒

Aldose Reductase Inhibitors for the Treatment of Diabetic Neuropathy,defined end points and the inability to produce an inhibitor that achieves satisfactory tissue penetration and enzyme inhibition are other major contributing factors for this failure. This chapter focuses on the clinical trials that have examined the effect of all tested ARIs on human diabetic neuropathy.